ABC suction sequence: Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
ACB suction sequence: Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
BAC suction sequence: Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
BCA suction sequence: Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
CAB suction sequence: Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
CBA suction sequence: Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
Study summary
The goal of this clinical study is to compare the tissue adequacy, cellularity, blood contamination, accuracy, sensitivity, specificity of the 22G Trident needle combined with three different aspiration techniques (dry-suction, wet-suction, and slow-pull) in Endoscopic ultrasound-guided fine-needle biopsy for solid pancreatic lesions.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* (Before the trial, subjects must meet all of the requirements listed below in order to be enrolled)
1. 18-80 years old (inclusive), male and female;
2. patients with pancreatic solid mass \> 1cm detected by CT/MRI/PET-CT or EUS and requiring EUS-FNB diagnosis.
3. written informed consent was obtained.
Exclusion Criteria:
* (Before the trial, participants could not be enrolled if they met any of the following requirements)
1. contraindications to endoscopy, such as severe cardiovascular and cerebrovascular diseases;
2. bleeding coagulation dysfunction (prothrombin international normalized ratio ≥1.5, platelet count ≤ 50 000) or use of antiplatelet drugs;
3. confirmed pregnancy or possible pregnancy;
4. pathological diagnosis has been obtained by other methods;
5. refuse to participate in the study, are participating in another observational clinical trial, or have participated in another clinical trial within 60 days.
6. other situations where EUS-FNB could not be performed.
Primary outcome measure(s)
Tissue adequacy — 2 months Grade A, existing core tissue (defined as structurally intact tissue with a long axis length of at least 550 μm) that clearly characterizes the lesion and is sufficient for diagnosis; Grade B, the presence of core fragments that do not meet the histological criteria for structural integrity, but can still be diagnosed based on cell morphology; Grade C, no diseased tissue is found and no diagnosis can be made based on the sample.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.